Multiomics Blood Biomarkers Predict Alzheimer from predementia with High Specificity

To cite this version:

HAL Id: hal-04522821
https://hal.science/hal-04522821
Submitted on 27 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License
BIOMARKERS (NON-NEUROIMAGING)

Multiomics Blood Biomarkers Predict Alzheimer from predementia with High Specificity

Benoit Souchet1 | Alkéos Michaïl1 | Maud Heuillet2 | Aude Dupuy-Gayral2 | Eloi Haudebourg2 | Catherine Pech2 | Antoine Berthemy2 | Baptiste Billoir1 | François Autelitano2 | Juan Fortea3 | Christopher J Fowler4 | Suman Jayadev5 | Alberto Lleo3 | Colin L Masters4 | Francois Mouton-Liger6 | Claire Paquet6 | Jerome Braudeau1

1AgenT SAS, Evry, France  
2Evotec (France) SAS, Toulouse, France  
3Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain  
4The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia  
5University of Washington, Seattle, WA, USA  
6Cognitive Neurology Center, Hôpital Lariboisière-Fernand Widal APHP, Paris, France

Correspondence
Jerome Braudeau, AgenT SAS, Evry France. Email: jerome.braudeau@agent-biotech.com

Abstract

Background: The core criteria for mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) is based in part on cognitive criteria and biological evidence of at least moderately frequent amyloid plaques (Albert et al., 2011; McKhann et al., 2011). They predict AD among cognitively impaired patients with high sensitivity but low specificity (Kokkinou et al. 2021; Martinez et al. 2017; Ritchie et al. 2014): up to 25% of amyloid-positive patients would be misdiagnosed as AD while suffering from another brain disorder. Therefore, there is a need to develop new biomarkers with high specificity to facilitate earlier diagnosis, rapid therapeutic intervention and monitoring of clinical trials.

Method: Targeted mass spectrometry assays were developed for 81 blood biomarkers (45 proteins and 36 metabolites) pre-identified in AAV-AD rats (Audrain et al. 2018). 345 cognitively impaired participants (193 MCI and 152 demented) were collected in plasma at baseline and followed clinically from 1 to 13 years. Participants’ diagnosis (AD, or non-AD) was established at the last clinical visit based on cognitive diagnosis standard for each brain disorder subtype. 82.9% of participants had available amyloid status at baseline, 61.9% were determined as amyloid positive. Each clinical group contained amyloid positive and negative participants. Predictive machine learning models for AD participants (n = 123 Prodromal AD, n = 126 AD dementia) among individuals with Non-AD brain disorder (Non-AD, n = 96) was developed. The training dataset (70%) aimed to select the biomarkers subset, train the algorithm, and define the cut-off. External test dataset (30%) aimed to validate in blind the locked predictive model.

Result: With 19 blood biomarkers and age, the model predicted AD participants (n = 41 Prodromal AD, n = 43 AD dementia) from non-AD participants (n = 25) with 92.0% specificity and 52.4% sensitivity during external validation (AUROC = 71.8%, p = 0.001). When amyloid status (CSF or PET) and this predictive ML model were applied...
in series, and participants positive for both were predicted as AD. 100% specificity and 39.7% sensitivity were achieved.

Conclusion: Multiomics blood peripheral biomarkers predicted AD patients among cognitively impaired population with low FPR. In combination with amyloid screening, these biomarkers could identify a nearly pure AD population.